These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20542674)

  • 1. Ductal variant of adenocarcinoma prostate responding to docetaxel--a case report.
    Paterson C; Correa PD; Russell JM
    Clin Oncol (R Coll Radiol); 2010 Sep; 22(7):617. PubMed ID: 20542674
    [No Abstract]   [Full Text] [Related]  

  • 2. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
    BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
    Guancial EA; Taplin ME
    Clin Genitourin Cancer; 2011 Dec; 9(2):130-2. PubMed ID: 21816687
    [No Abstract]   [Full Text] [Related]  

  • 4. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
    Di Lorenzo G; Bracarda S; Buonerba C; Aieta M; Mirone V
    Eur Urol; 2014 Feb; 65(2):505-7. PubMed ID: 24211139
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
    Helley D; Banu E; Bouziane A; Banu A; Scotte F; Fischer AM; Oudard S
    Eur Urol; 2009 Sep; 56(3):479-84. PubMed ID: 18585841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer metastasis to supraclavicular lymph node.
    Hobdy EM; Shafi NQ; Kummar S
    Clin Adv Hematol Oncol; 2004 Apr; 2(4):223-4; discussion 224. PubMed ID: 16163185
    [No Abstract]   [Full Text] [Related]  

  • 9. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
    Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Docetaxel for advanced prostate cancer].
    Inagaki T; Hara I
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():525-30. PubMed ID: 22208038
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; George DJ
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):108-16. PubMed ID: 20066005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.
    Sorscher SM
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):191-2. PubMed ID: 15148627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel for hormone-sensitive metastatic prostate cancer.
    Baker H
    Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
    [No Abstract]   [Full Text] [Related]  

  • 16. Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.
    Buonerba C; Palmieri G; Di Lorenzo G
    Eur Urol; 2010 Oct; 58(4):636-7. PubMed ID: 20580484
    [No Abstract]   [Full Text] [Related]  

  • 17. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
    Gebbia V; Serretta V; Borsellino N; Valerio MR;
    Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
    Protheroe A
    Nat Clin Pract Oncol; 2005 Feb; 2(2):68-9. PubMed ID: 16264873
    [No Abstract]   [Full Text] [Related]  

  • 19. Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer.
    Talebi TN; Manoharan M; Singal R
    Am J Ther; 2012 Jan; 19(1):e59-61. PubMed ID: 20535002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of prostate cancer with a large abdominal mass effectively treated with a high dose of diethylstilbestrol-diphosphate.
    Wakisaka M; Takagishi H
    Hinyokika Kiyo; 1993 Sep; 39(9):849-51. PubMed ID: 8213382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.